Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of motexafin gadolinium and docetaxel for second line treatment of patients with advanced non-small cell lung cancer.

Trial Profile

Phase II trial of motexafin gadolinium and docetaxel for second line treatment of patients with advanced non-small cell lung cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Motexafin gadolinium (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 24 Oct 2013 According to ClinicalTrials.gov record, status changed from completed to discontinued.
    • 19 Aug 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 13 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top